

Synthesis and Antihypertensive Activity of Pyran Oxygen and Amide Nitrogen Replacement Analogues of the Potassium Channel Activator Cromakalim

Valerie A. Ashwood,[†] Frederick Cassidy,[†] John M. Evans,^{*,†} Stefania Gagliardi,[†] and Geoffrey Stemp^{*,†}

SmithKline Beecham Pharmaceuticals, Coldharbour Road, The Pinnacles, Harlow, Essex, CM19 5AD England, and Zambelletti SpA., Via Zambelletti, 20021 Baranzate, Milan, Italy. Received April 15, 1991

The synthesis and oral antihypertensive activity in conscious spontaneously hypertensive rats of two new series of compounds related to the prototype potassium channel activator cromakalim (1) are described. In the first series, replacement of the benzopyran oxygen atom by nitrogen or methylene led to the 1,2,3,4-tetrahydroquinoline 12 and 1,2,3,4-tetrahydronaphthalene 13, which were both less active than 1. However, in contrast to the equivalent activity found previously for 1 and its dehydrated analogue 28, the dihydronaphthalene 27 was found to be more active than 13. In the second series, replacement of the C(4) amide nitrogen atom in acyclic amides related to cromakalim by methylene gave ketone 16 that was less active than the corresponding amide 15. However, replacement of the 4-acetyl substituent in 16 by *N,N*-dimethylacetamido as in compound 22 resulted in a marked enhancement in activity. The compounds described in this paper thus illustrate the importance of the benzopyran oxygen and C(4) substituent on antihypertensive activity in the cromakalim series of potassium channel activators.

Following the emergence of cromakalim (1),^{1,2} the prototype channel activator, other examples of this potentially important class of agent have been reported. Among these (see Chart I) are the established vasodilator pinacidil (2), minoxidil sulfate (3), diazoxide (4), and RP 49356 (5).³ More recently, potassium channel activators based on the benzopyran nucleus, such as EMD 52692 (6),⁴ SDZ PCO 400 (7),⁵ and Ro 31-6930 (8),⁶ have been disclosed.

In subsequent studies on antihypertensive benzopyran potassium channel activators, we have investigated the effect of incorporation of acyclic amido substituents at C(4)⁷ in lieu of the pyrrolidinone group present in compound 1. Furthermore the C(6) electron-withdrawing group has been replaced by alkyl substituents,⁸ and the benzopyran nucleus has been replaced by the pyrano-[3,2-*c*]pyridine nucleus.⁸


Besides providing active antihypertensive agents,^{1,7,8} it has been established that potassium channel activators have potential use in the treatment of bronchial asthma, and certain analogues described previously^{1,8} have been shown⁹ by our colleagues to be potent relaxants of guinea pig tracheal tissue.

As part of our continuing study on structural modification of compound 1 and related acyclic amides, it was decided to investigate the effect on antihypertensive activity of replacing the pyran oxygen atom by a carbon or a nitrogen atom, and the nitrogen atom at C(4) by a carbon atom. Hence this paper describes the synthesis of a series of 2,2-dimethyl-1,2,3,4-tetrahydroquinolines, -naphthalenes, and their dihydro derivatives, and benzopyrans containing substituents at C(4) linked by carbon and their evaluation in the spontaneously hypertensive rat (SHR) in comparison with compound 1. Also included in Table I are compounds 15, 18, 20, and 28, which have been reported in our earlier publications,^{7,8} that provide a more meaningful comparison of activities, being structurally closer than compound 1 to certain of the compounds described in this study.

Chemistry

Although the 6-chloro- (29) and 6-bromo-2,2-dimethyl-1,2-dihydroquinolines (30, Scheme I) were readily prepared following the literature¹⁰ procedure, the 6-cyano analogue 31 could not be prepared using this method. Consequently the synthetic approach relied on halogen replacement during the ultimate stage. The dihydroquinolines 29 and 30 could not be directly epoxidized with

Chart I




m-chloroperbenzoic acid or hydrobrominated with aqueous NBS. However, *N*-acetylation of compounds 29 and 30

- (1) Ashwood, V. A.; Buckingham, R. E.; Cassidy, F.; Evans, J. M.; Faruk, E. A.; Hamilton, T. C.; Nash, D. J.; Stemp, G.; Willcocks, K. Synthesis and Antihypertensive Activity of 4-(Cyclic amido)-2*H*-1-benzopyrans. *J. Med. Chem.* 1986, 29, 2194-2201.
- (2) Hamilton T. C.; Weir, S. W.; Weston, A. H. Comparison of the Effects of BRL 34915 and Verapamil on Electrical and Mechanical Activity in Rat Portal Vein. *Br. J. Pharmacol.* 1986, 88, 103-111.
- (3) Robertson, D. W.; Steinberg, M. I. Potassium Channel Modulators: Scientific Applications and Therapeutic Promise. *J. Med. Chem.* 1990, 33, 1529-1541 and references therein.
- (4) Bergmann, R.; Gericke, R. Synthesis and Antihypertensive Activity of 4-(1,2-Dihydro-2-oxo-1-pyridyl)-2*H*-1-benzopyrans and Related Compounds, New Potassium Channel Activators. *J. Med. Chem.* 1990, 33, 492-503.
- (5) Quast, U.; Blarer, S.; Manley, P. W.; Cook, N. S.; Pally, C.; Fozard, J. R. The Cardiovascular Effects of SDZ PCO 400, a Novel K⁺ Channel Opener. *Br. J. Pharmacol.* 1990, 99, 7P.
- (6) Paciorek, P. M.; Burden, D. T.; Burke, Y. M.; Cowlrick, I.; Perkins, R. S.; Taylor, J. C.; Waterfall, J. F. Preclinical Pharmacology of Ro 31-6930, a New Potassium Channel Opener. *J. Cardiovasc. Pharmacol.* 1990, 15, 188-192.
- (7) Ashwood, V. A.; Cassidy, F.; Coldwell, M. C.; Evans, J. M.; Hamilton, T. C.; Howlett, D. R.; Smith, D. M.; Stemp, G. Synthesis and Antihypertensive Activity of 4-(Substituted-carbonylamino)-2*H*-1-benzopyrans. *J. Med. Chem.* 1990, 33, 2667-2672.

[†]SmithKline Beecham Pharmaceuticals.

[†]Zambelletti SpA.

Scheme I




gave compounds **32** and **33**, respectively, which underwent the hydrobromination reaction with moist NBS to yield compounds **34** and **35**, respectively. Basic treatment of the bromohydrins furnished the epoxides **36** and **37**, respectively (Scheme I).


Reaction of the 6-chloro epoxide **36** with the anion of 2-pyrrolidinone in DMSO gave a mixture of the *cis*- and *trans*-tetrahydroquinolines **38** and **9**, respectively, and the dihydroquinoline **24**. Similarly, the 6-bromo epoxide **37** gave the *cis*- and *trans*-tetrahydroquinolines, **39** and **11**, respectively, and the dihydroquinoline **25**. In each case the *N*-acetyl group was removed during the reaction. A probable explanation for the formation of *cis* and *trans* products in these reactions is via the mechanism shown in Scheme I, involving initial attack on the *N*-acetyl group and formation of a planar intermediate, which is supported by data on closely related compounds.¹¹

The *trans*-6-bromotetrahydroquinoline **11** and the dihydroquinoline **25** were both converted to the C(6)-cyano analogues **12** and **26**, respectively, on treatment with an excess of Cu(I)CN in *N*-methylpyrrolidinone (NMP). Interestingly, under similar conditions, the *cis*-tetrahydroquinoline **39** product rearranged to give the indole **40** as

Scheme II



Scheme III




the sole product (65%), possibly by the process depicted in Scheme II.

Synthesis of the tetrahydronaphthalene analogues employed 4-bromobenzyl bromide as starting material (Scheme III). Formation of the Grignard reagent and reaction with diethyl isopropylidenemalonate gave the bromophenyl malonate **41**. A standard basic hydrolysis furnished the diacid **42**, which was thermally decarboxylated to the butanoic acid derivative **43**. Ring closure was accomplished with phosphoric acid at 100 °C to give 7-bromodihydronaphthalen-1-one **44**, which in turn was reduced to the alcohol **45** with borohydride. Elimination of

- Burrell, G.; Cassidy, F.; Evans, J. M.; Lightowler, D.; Stemp, G. Variation in the Aromatic Ring of Cromakalim: Antihypertensive Activity of Pyranopyridines and 6-Alkyl-2*H*-1-benzopyrans. *J. Med. Chem.* 1990, 33, 3023-3027.
- Arch, J. R. S.; Buckle, D. R.; Fenwick, A. E.; Houge-Frydrych, C. S. V.; Pinto, I. L.; Smith, D. G.; Taylor, S. G.; Tedder, J. M. Relaxant Activity of 4-Amido-3,4-dihydro-2*H*-1-benzopyrans in Guinea Pig Isolated Trachealis. *J. Med. Chem.* 1990, 33, 3028-3034.
- Dillard, R. B.; Pavey, D. E.; Bensley, D. N. Synthesis and Antiinflammatory Activity of Some 2,2-Dimethyl-1,2-dihydroquinolines. *J. Med. Chem.* 1973, 16, 251-253.
- Evans, J. M.; Gagliardi, S.; Stemp, G. Unpublished results.


Table I. Pyran Oxygen and C(4) Nitrogen Replacement Analogues of Cromakalim (1)



no.	R ₁	R ₂	R ₃	X	yield, %	mp, °C	recryst solvent ^a	formula	anal. ^b	dose, mg/kg	max fall ^c in bp, % ± SEM
1 ^d	CN	c-NCO(CH ₂) ₃	OH	O						0.3	39 ± 4
										1.0	47 ± 1
9	Cl	c-NCO(CH ₂) ₃	OH	NH	19	82–85	E-P	C ₁₅ H ₁₉ N ₂ O ₂ Cl	C,H;N ^e	10.0	8 ± 3
10 ^d	Cl	c-NCO(CH ₂) ₃	OH	O						10.0	37 ± 7
11	Br	c-NCO(CH ₂) ₃	OH	NH	30	93–102	C	C ₁₅ H ₁₉ N ₂ O ₂ Br	M ^f	10.0	6 ± 3
12	CN	c-NCO(CH ₂) ₃	OH	NH	25	297–298	E	C ₁₆ H ₁₉ N ₃ O ₂	C,H,N	1.0	9 ± 5
										3.0	26 ± 5
										10.0	39 (n = 2)
13	CN	c-NCO(CH ₂) ₃	OH	CH ₂	53	203–204	E	C ₁₇ H ₂₀ N ₂ O ₂	C,H,N	3.0	29 ± 2
										10.0	32 ± 4
14	CN	NHCOMe	OH	CH ₂	35	203–205	E-P	C ₁₅ H ₁₈ N ₂ O ₂	C,H,N	1.0	22 ± 2
										3.0	34 ± 4
15 ^g	CN	NHCOMe	OH	O					C,H,N	0.1	18 ± 2
										0.3	47 ± 5
										1.0	67 ± 4
16	CN	CH ₂ COMe	OH	O	19	114–115	E-P	C ₁₅ H ₁₇ NO ₃	C,H,N	1.0	5 ± 4
										10.0	30 ± 6
17	CN	NHCOPh	OH	CH ₂	70	205–207	E-PE	C ₂₀ H ₂₀ N ₂ O ₂	C,H,N	3.0	16 ± 4
										10.0	44 ± 3
18	CN	NHCOPh	OH	O						0.3	16 ± 3
										1.0	41 ± 8
19	CN	NHCONHMe	OH	CH ₂	68	209.5–211	E-M	C ₁₅ H ₁₉ N ₃ O ₃	C,H,N	3.0	23 ± 2
										10.0	52 ± 2
20 ^h	CN	NHCONHMe	OH	O						0.3	31 ± 9
										1.0	61 ± 3
21	CN	CH ₂ CONHMe	OH	O	10	141–142	E	C ₁₅ H ₁₈ N ₂ O ₃	C,H,N	3.0	9 ± 6
22	CN	CH ₂ CONMe ₂	OH	O	24	174–175	E-PE	C ₁₆ H ₂₀ N ₂ O ₃	C,H,N	1.0	28 ± 4
										3.0	51 ± 3
23	CN	c-CHCONMe(CH ₂) ₂	OH	O	20	236–237	E-PE	C ₁₇ H ₂₀ N ₂ O ₃	C,H,N	3.0	10 ± 2
										10.0	21 ± 3
24	Cl	c-NCO(CH ₂) ₃	Δ ^{3,4}	NH	45	158–159	E-PE	C ₁₅ H ₁₇ N ₂ OCl	C,H,N	10.0	13 ± 2
25	Br	c-NCO(CH ₂) ₃	Δ ^{3,4}	NH	15	177–178	E-P	C ₁₅ H ₁₇ N ₂ OBr	C,H,N	10.0	4 ± 1
26	CN	c-NCO(CH ₂) ₃	Δ ^{3,4}	NH	50	207–209	E-P	C ₁₆ H ₁₇ N ₃ O	C,H,N	1.0	10 ± 3
										3.0	29 ± 4
										10.0	49 ± 4
27	CN	c-NCO(CH ₂) ₃	Δ ^{3,4}	CH ₂	19	131–132	E-P	C ₁₇ H ₁₈ N ₂ O	C,H,N	1.0	23 ± 6
										3.0	50 ± 2
28 ^d	CN	c-NCO(CH ₂) ₃	Δ ^{3,4}	O			E-PE			0.1	12 ± 3
										0.3	47 ± 5

^aC = chromatography, E = EtOAc, PE = 60–80 °C petroleum ether, P = pentane. ^bAnalysis for the elements indicated were within ±0.4% of the theoretical values. ^cSystolic blood pressure was measured indirectly at intervals from 1 to 6 h in groups of six SH rats per dose level, unless indicated. ^dSee ref 1. ^eN: calcd, 9.52; found, 8.96. ^fMass (C₁₅H₁₉N₂O₂Br) found *m/z* 338.0639, calcd 338.0630. ^gSee ref 7.

Scheme IV



water from alcohol 45 gave the bromodihydronaphthalene 46, which was converted to the 7-cyano analogue 47 using Cu(I)CN in refluxing NMP. Compound 47 was then

subjected to our usual procedure,¹ giving the epoxide 49 via the bromohydrin 48. However, unlike the formation of compound 1 from its precursor epoxide 51,⁷ problems were encountered when the same conditions were applied to epoxide 49, as treatment with pyrrolidin-2-one anion resulted in the formation of the 3,4-dihydronaphthalene 27. Hence formation of the desired analogue 13 of compound 1 required the preparation of the amino alcohol 50, followed by acylation with chlorobutyl chloride and ring closure under basic conditions. Amino alcohol 50 was acylated with acetyl chloride and benzoyl chloride to give the acetylamino (14) and benzoylamino (17) analogues, respectively, while reaction with methyl isocyanate yielded the methylurea 19.

Epoxide 51 (Scheme IV) was treated with the dilithium anion of *tert*-butyl acetoacetate using a literature procedure¹² to give the butyrate 52. Hydrolysis and decarboxylation provided the methyl ketone 16. In order to prepare

(12) Kieczkowski, G. R.; Quesada, M. L.; Schlessinger, R. H. Total Synthesis of dl-Bisnorvernolepin. *J. Am. Chem. Soc.* 1980, 102, 782–790.

the C(4) carbon analogue **21** of urea **20**,⁷ epoxide **51** was treated with *N*-methyl-*N*-(4-methoxybenzyl)acetamide and lithium diisopropylamide generated in situ, and the resulting compound **53** was debenzylated by treatment with methanesulfonic acid during 6 days to give the requisite compound **21**. The *N,N*-dimethyl compound **22** was obtained directly from epoxide **51** by the action of *N,N*-dimethylacetamide, again using lithium diisopropylamide as the base, and a similar reaction using NMP gave the cyclic analogue **23**.

Results and Discussion

The compounds of Table I were evaluated for oral antihypertensive activity in the SHR. Systolic blood pressure, recorded from the tail, was determined before dosing and at various time intervals during the ensuing 6 h. Maximum falls in blood pressure obtained for all the compounds occurred between 1 and 4 h postdose, with some recovery to the predose level of blood pressure being observed at 6 h.

The replacement of the pyran oxygen atom, both by the nitrogen atom and methylene group as in compounds **12** and **13**, respectively, furnished compounds of approximately equal activity to each other, both being approximately 10-fold less active than cromakalim **1**.¹ The chloro (**9**) and bromo (**11**) analogues demonstrated little activity at the top dose investigated in this study, unlike the corresponding chlorobenzopyran compound **10**.¹ It has been shown⁷ that the C(4)-acetylamino substituent, as in compound **15** conferred high activity in the benzopyran series, being slightly more active than the C(4)-pyrrolidinone substituent, as in compound **1**. In the tetrahydronaphthalene series the acetylamino compound **14** showed similar activity to that of the pyrrolidinone compound **13**. However, the general trend of reduced activity in the tetrahydronaphthalene series compared with the benzopyran series is exemplified by acetylamino compound **14**, benzamide **17**, and methylurea **19**, which are up to 1 order of magnitude less active than their benzopyran counterparts **15**, **18**, and **20**, respectively.

Of the dihydroquinolines, the C(6)-halogenated compounds **24** and **25** were only slightly active at 10 mg/kg. In contrast the C(6)-cyano compound **26** showed enhanced activity, presumably due to the presence of the stronger electron withdrawing substituent, but was much less active than the benzopyran analogue **28**. Although in general the tetrahydroquinoline and -naphthalene series were comparable in activity, an exception was noted in the dihydronaphthalene **27**, which was approximately twice as active as the corresponding dihydroquinoline **26**, but again was less active than the benzopyran **28**. It is noteworthy that dihydronaphthalene **27** is approximately twice as active as tetrahydronaphthalene **13**, in contrast to the similar activities observed for the corresponding benzopyrans **28** and **1**.

In replacement of the nitrogen atom at C(4) by a methylene unit, the ketone **16** and amides **21** and **23** were all very much less active than their corresponding C(4) analogues **15**, **20**, and **1**, respectively. Presumably the tetrahedral nature of the carbon atom attached to C(4) in the analogues **16**, **21**, and **23** alters the configuration of the ubiquitous carbonyl group by moving the substituent out of the orthogonal disposition with respect to the benzopyran nucleus that we have commented on previously.¹³

Interestingly, amide **22** with a second *N*-methyl group is markedly more active than amide **21**. One can speculate that the additional methyl group increases the probability of the amide group adopting the optimal conformation for activity.

In the series of compounds presented here, it can be seen that replacement of either the pyran oxygen atom by a nitrogen atom or a methylene group or the C(4) nitrogen atom by a methylene group, provides compounds that, in general, are less active as antihypertensive agents in the SHR. Nevertheless, this study has provided compounds (**22** and **27**) that are comparable in activity to many of the compounds reported previously,^{1,7,8} together with compound **12**, which has been shown to have potential for the treatment of cerebrovascular disorders.¹⁴ It also illustrates the importance of two further features, namely the pyran oxygen atom and the nature of C(4) substituent, in conferring optimal antihypertensive activity in the cromakalim series of potassium channel activators.

Experimental Section

Melting points were determined with a Büchi capillary melting point apparatus and are uncorrected. IR, NMR, and mass spectra, which were in agreement with the structures cited, were recorded on a Perkin-Elmer 197 or 599 for IR, a Varian EM 360A at 60 MHz, a Varian CFT-20 at 80 MHz, or a JEOL GX 270 for NMR, and a VG70-70 or 70 ZAB at 70 eV for mass spectra, respectively. HF₂₅₄ silica gel plates were used for chromatotron chromatography (radial chromatography) and Kieselgel 60 for column chromatography.

Anhydrous Na₂SO₄ was used as a drying agent for organic extractions throughout. Petroleum ether refers to the fraction boiling at 60–80 °C.

6-Chloro- and 6-Bromo-2,2-dimethyl-1,2-dihydroquinoline (29 and 30, Respectively). The compounds were prepared from the corresponding anilines following the literature¹⁰ methods A and C, with that of compound **30** employing Cu(I)Br.

Compound **29**: 36%; bp 85–100 °C (0.06 mmHg); NMR (CDCl₃) δ 1.25 [s, 6 H, C(Me)₂], 3.45 (s, NH), 5.35 (d, 9, H-3), 6.10 (d, 9, H-4), 6.20 (d, 10, H-8), 6.70 (m, H-5 and H-7); mass spectrum (C₁₁H₁₂NCl) found *m/z* 193.0658, calcd 193.0658.

Compound **30**: 33%; bp 90–102 °C (0.03 mmHg); mass spectrum (C₁₁H₁₂NBr) found *m/z* 237.0152, calcd 237.0154.

1-Acetyl-6-chloro- and 1-Acetyl-6-bromo-2,2-dimethyl-1,2-dihydroquinoline (32 and 33, Respectively). Acetyl chloride (12 mL, 0.083 mol) was added dropwise to a stirred solution of compound **29** (16 g, 0.083 mol) and *N,N*-diethylaniline (24 mL, 0.19 mol) in CH₂Cl₂ (200 mL) at 0 °C. The solution was stirred at room temperature for an additional 24 h and then poured into H₂O, and the organic layer was separated. The organic layer was washed with 1 N HCl, 5% NaHCO₃ solution, H₂O, and brine and dried. Filtration and evaporation gave the crude *N*-acetyl derivative **32** as a brown gum (18.9 g, 97%): NMR (CDCl₃) δ 1.50 [s, 6 H, C(Me)₂], 2.10 (s, 3 H, NCOMe), 5.60 (d, 10, H-3), 6.15 (d, 10, H-4), 6.60 (d, 8, H-8), 6.90 (m, H-5 and H-7); mass spectrum (C₁₃H₁₄ClNO) found *m/z* 235.0766, calcd 235.0764.

Compound **33** was prepared in a similar manner as a pale yellow oil: 96%; NMR (CDCl₃) δ 1.50 [s, 6 H, C(Me)₂], 2.12 (s, 3 H, COMe), 5.61 (d, 10, H-3), 6.17 (d, 10, H-4), 6.57 (d, 8, H-8), 7.03 (narrow m, H-5) overlapping 7.11 (q, 8, 2, H-7).

trans-1-Acetyl-3-bromo-6-chloro-2,2-dimethyl-1,2,3,4-tetrahydroquinolin-4-ol (34) and trans-1-Acetyl-3,6-dibromo-2,2-dimethyl-1,2,3,4-tetrahydroquinolin-4-ol (35). NBS (16.0 g, 0.09 mol) was added to a vigorously stirred solution of compound **32** (18.9 g, 0.08 mol) in DMSO (150 mL) and H₂O (15 mL, 0.83 mol). The mixture was stirred for 1 h at room temperature and then diluted with H₂O and extracted with EtOAc. The organic extracts were washed with H₂O and brine and dried. Filtration and evaporation gave the bromohydrin **34** as a dark brown gum (26.5 g, 99%): mass spectrum (C₁₃H₁₅BrClNO₂) found

(13) Cassidy, F.; Evans, J. M.; Smith, D. M.; Stemp, G.; Edge, C.; Williams, D. J. Conformational Analysis of the Novel Antihypertensive Agent Cromakalim (BRL 34915). *J. Chem. Soc., Chem. Commun.* 1989, 377–378.

(14) Angersbach, D.; Evans, J. M.; Nicholson, C. D.; Stemp, G. U.S. Pat. Appl. US 4,808,619, 1989.

m/z 374.9476, calcd 374.9471.

Similarly prepared was compound 35 (93%) as a black gum: NMR (CDCl_3) δ 1.68 [s, 6 H, C(Me) $_2$], 2.08 (s, 3 H, NCOMe), 3.79 (d, 9, H-3), 4.70 (d, 9, H-4), 6.70 (d, 8, H-8), 7.27 (q, 8, 2, H-7), 7.60 (narrow m, H-5); IR (film) 3310, 1660 cm^{-1} ; mass spectrum ($\text{C}_{13}\text{H}_{15}\text{NO}_2\text{Br}_2$) found m/z 374.9476, calcd 374.9471.

1-Acetyl-6-chloro- and 1-Acetyl-6-bromo-2,2-dimethyl-3,4-epoxy-1,2,3,4-tetrahydroquinoline (36 and 37, Respectively). A mixture of compound 34 (26.5 g, 0.08 mol) and KOH pellets (25 g, 0.45 mol) in dry Et_2O (500 mL) was stirred vigorously at room temperature for 48 h. Filtration and evaporation gave epoxide 36 (18.5 g, 92%) as a dark colored gum which was used directly in the next stage: NMR (CDCl_3) δ 1.20 (s, 3 H, Me), 1.85 (s, 3 H, Me), 2.10 (s, 3 H, COMe), 3.35 (d, 4, H-3), 3.75 (d, 4, H-4), 6.65 (d, 9, H-8), 7.15 (m, H-5 and H-7).

Similarly prepared was compound 37 (83%) as a dark green gum: mass spectrum ($\text{C}_{13}\text{H}_{14}\text{NO}_2\text{Br}$) found m/z 295.0217, calcd 295.0208.

cis- and trans-6-Chloro-2,2-dimethyl-4-(2-oxopyrrolidinyl)-1,2,3,4-tetrahydroquinolin-3-ols (38 and 9, Respectively) and 6-Chloro-2,2-dimethyl-4-(2-oxopyrrolidinyl)-1,2-dihydroquinoline (24). Pyrrolidin-2-one (1.28 g, 15 mmol) was added to a suspension of NaH (0.52 g of 80% oil dispersion, 17 mmol) in DMSO (100 mL) under N_2 , and the mixture was stirred for 10 min. A solution of epoxide 36 (3.6 g, 15 mmol) in DMSO (10 mL) was added to the solution, which was stirred at room temperature for 4 h. Water was added cautiously to the reaction mixture, which was extracted with EtOAc. The organic layer was washed with brine and dried. Filtration and evaporation gave a crude product which was chromatographed on silica gel. Elution with 5% MeOH- CH_2Cl_2 gave compound 24 (0.4 g; see Table I), followed by compound 38 (0.8 g, 19%) and compound 9 (0.8; see Table I). 38: mp 64–65 °C as the hemihydrate; NMR (CDCl_3) δ 1.20 [s, 6 H, C(Me) $_2$], 2.05 (m, 3 H, NCH_2CH_2 and NH), 2.50 (m, 2 H, COCH_2), 3.55 (m, NCH_2 and H-4), 5.45 (d, 3.5, H-4), 6.50–7.10 (m, 3 ArH). Anal. ($\text{C}_{15}\text{H}_{19}\text{N}_2\text{O}_2\text{Cl}\cdot 0.5\text{H}_2\text{O}$) C, H, N. The remaining fractions contained starting epoxide 36 (>40%).

Similarly prepared were the 6-bromo analogues 11, 25 (see Table I), and the cis compound 39. 39: a yellow solid; mp 76–80 °C; NMR (CDCl_3) δ 1.25 [s, 6 H, C(Me) $_2$], 2.05 (m, 2 H, NCH_2CH_2), 2.25 (d, 10, OH), 2.50 (m, 2 H, COCH_2), 3.30 (m, 1 H, NCH_2), 3.60 (m, 1 H, NCH_2), 3.65 (q, 10, 4, collapsing to d, 4, on addition of D_2O H-3), 3.80 (m, NH), 5.45 (d, 4, H-4), 6.45 (d, 8, H-8), 7.10 (m, H-5 and H-7); mass spectrum ($\text{C}_{15}\text{H}_{19}\text{N}_2\text{O}_2\text{Br}$) found m/z 338.0635, calcd 338.0603.

trans-6-Cyano-2,2-dimethyl-4-(2-oxopyrrolidinyl)-1,2,3,4-tetrahydroquinolin-3-ol (12). A solution of compound 11 (0.37 g, 1.1 mmol) and Cu(I)CN (0.2 g, 2.2 mmol) in NMP (10 mL) was refluxed for 4 h. The mixture was cooled and poured into 10% aqueous ethylenediamine and extracted with EtOAc. The organic phase was washed with H_2O , and dried. Filtration and evaporation gave compound 12 as white microcrystals (76 mg; see Table I).

5-Cyano-3-(2-oxopyrrolidinyl)-2-isopropylindole (40). A solution of compound 39 (0.5 g, 1.5 mmol) and Cu(I)CN (0.25 g, 2.8 mmol) in NMP (25 mL) was refluxed for 4 h. The solution was cooled and poured into 10% aqueous ethylenediamine and extracted with EtOAc. The organic phase was washed with 10% aqueous ethylenediamine and dried. Filtration and evaporation gave a gum which was radially chromatographed using a gradient elution from EtOAc-pentane to EtOAc. The product was recrystallized from EtOAc-pentane to give compound 40 (0.26 g, 65%): mp 249–250 °C; NMR (CDCl_3) δ 1.22 [d, 7, 6 H, C(Me) $_2$], 2.35 (m, 2 H, NCH_2CH_2), 2.65 (m, 2 H, COCH_2), 3.05 [sp, 7, 1 H, C(Me) $_2$], 3.77 (t, 7, 2 H, NCH_2), 7.30 (m, H-6 and H-7), 7.70 (d, 1.5, H-4), 9.05 (m, NH). Anal. ($\text{C}_{16}\text{H}_{17}\text{N}_3\text{O}$) C, H, N.

Diethyl [2-(4-Bromophenyl)-1,1-dimethylethyl]malonate (41). A solution of *p*-bromobenzyl bromide (25 g, 0.1 mol) in dry Et_2O (200 mL) was added dropwise to a suspension of Mg turnings (2.4 g, 0.1 mol), under N_2 , at such a rate as to maintain reflux. The mixture was refluxed for an additional 1.5 h and cooled to 0 °C. Cu(I)Cl (0.2 g, 2 mmol) was added to the solution which was vigorously stirred for 5 min. A solution of diethyl isopropylidene malonate (15 g, 74 mmol) in Et_2O (50 mL) was added dropwise to the reaction mixture, with cooling to 0–5 °C. The mixture was allowed to attain room temperature with stirring

during 1 h and then poured into dilute H_2SO_4 . The layers were separated, and the aqueous phase was extracted with Et_2O . The ether extract was washed with NaHCO_3 solution, H_2O , and brine and dried. Filtration, evaporation, and chromatography on silica gel using 10% Et_2O -petroleum ether gave compound 41 as an oil (17.0 g, 46%): NMR (CDCl_3) δ 1.10 [s, 6 H, C(Me) $_2$], 1.25 (t, 6 H, CH_2CH_3), 2.75 (s, 2 H, PhCH $_2$), 3.20 (s, CH), 4.15 (q, 4 H, CH_2CH_3), 6.90 (d, 8, 2 ArH), 7.25 (d, 8, 2 ArH).

[2-(4-Bromophenyl)-1,1-dimethylethyl]malonic Acid (42). A solution of compound 41 (17 g, 0.046 mmol) and KOH (17 g, 0.31 mol) in EtOH (100 mL) and H_2O (50 mL) was stirred at room temperature for 48 h. The solution was diluted with H_2O and extracted with EtOAc. Drying and removal of solvent and recrystallization from Me_2CO -petroleum ether gave the diacid 42 (8.0 g, 55%) with mp 169–173 °C: $\text{C}_{13}\text{H}_{15}\text{BrO}_4$ (C, H).

4-(4-Bromophenyl)-3,3-dimethylbutanoic Acid (43). Compound 42 (10.9 g, 0.035 mmol) was heated in an oil bath at 200 °C for 0.5 h to give the butanoic acid 43 (9.3 g, 99%). A small sample, recrystallized from 60–80 °C petroleum ether had mp 81–83 °C: mass spectrum ($\text{C}_{12}\text{H}_{15}\text{BrO}_2$) found m/z 270.0261, calcd 270.0256.

7-Bromo-3,3-dimethyl-3,4-dihydro-1(2H)-naphthalenone (44). A mixture of compound 43 (9.2 g, 34 mmol) and polyphosphoric acid (100 mL) was heated at 100 °C, with occasional swirling for 1 h. The solution was cooled, and H_2O (400 mL) was added cautiously. The solution was extracted with EtOAc, and the organic phase was washed with H_2O and brine and dried. Filtration and evaporation gave compound 44 (8.2 g, 95%) as a gum: NMR (CDCl_3) δ 1.05 [s, 6 H, C(Me) $_2$], 2.45 (s, 2 H, H-2), 2.75 (s, 2 H, H-4), 7.00 (d, 8, H-5), 7.45 (q, 8, 2, H-6), 8.05 (d, 2, H-8); mass spectrum ($\text{C}_{12}\text{H}_{13}\text{BrO}$) found m/z 252.0171, calcd 252.0150.

7-Bromo-3,3-dimethyl-1,2,3,4-tetrahydro-1-naphthol (45). A solution of compound 44 (7.8 g, 31 mmol) in dry EtOH (50 mL) at 0 °C was treated with NaBH_4 (1.5 g, 47 mmol). The mixture was stirred and allowed to attain room temperature during 18 h. Evaporation and partition of the residue between EtOAc and H_2O and drying and evaporation of the organic layer gave compound 45 (7.0 g, 89%): NMR (CDCl_3) δ 1.00 [s, 3 H, C(Me) $_2$], 1.20 [s, 3 H, C(Me) $_2$], 1.35–2.10 (m, 2 H, H-2), 2.20 (s, OH), 2.50 (s, 2 H, H-4), 4.80 (m, H-1), 6.90 (d, 8, H-5), 7.20 (q, 8, 3, H-6), 7.65 (d, 3, H-8); mass spectrum ($\text{C}_{12}\text{H}_{15}\text{OBr}$) found m/z 254.0310, calcd 254.0307.

7-Bromo-3,3-dimethyl-3,4-dihydronaphthalene (46). A solution of compound 45 (7.0 g, 28 mmol) and *p*-toluenesulfonic acid (0.5 g, 3 mmol) in PhH (100 mL) was refluxed for 1.5 h using a Dean-Stark H_2O separator. The solution was cooled, evaporated, and partitioned between Et_2O and H_2O . The organic layer was washed with NaHCO_3 solution, H_2O , and brine and dried. Filtration and evaporation gave compound 46 (6.2 g, 95%) as an oil: NMR (CDCl_3) δ 1.00 [s, 3 H, C(Me) $_2$], 2.55 [s, 3 H, C(Me) $_2$], 5.75 (d, 9, H-2), 6.20 (d, 9, H-1), 6.80–7.40 (m, 3 ArH); mass spectrum ($\text{C}_{12}\text{H}_{13}\text{Br}$) found m/z 236.0209, calcd 236.0201.

7-Cyano-3,3-dimethyl-3,4-dihydronaphthalene (47). A solution of compound 46 (6.2 g, 26 mmol) and Cu(I)CN (3.5 g, 39 mmol) in NMP (60 mL) was refluxed for 2 h. The solution was cooled and poured into 10% aqueous ethylenediamine (200 mL) and extracted with EtOAc. The organic layer was washed with H_2O and dried. Filtration and evaporation and chromatography on silica gel using 10% Et_2O -pentane as eluent gave compound 47 (4.6 g, 96%) as a crystalline solid with mp 50–52 °C. Anal. ($\text{C}_{13}\text{H}_{13}\text{N}$) C, H, N.

2-Bromo-7-cyano-3,3-dimethyl-1,2,3,4-tetrahydro-1-naphthol (48). NBS (5.0 g, 28 mmol) was added to a vigorously stirred solution of compound 47 (4.5 g, 25 mmol) in DMSO (50 mL) and H_2O (4 mL, 0.2 mol). The mixture was stirred at room temperature for 1 h, diluted with H_2O , and extracted with EtOAc. The organic extract was washed with H_2O and brine and dried. Filtration and evaporation gave the bromohydrin 48 as a colorless solid (7.0 g, 99%). A small portion, recrystallized from EtOAc, had a melting point of 164–165 °C. Anal. ($\text{C}_{13}\text{H}_{14}\text{NOBr}$) C, H, N.

7-Cyano-1,2-epoxy-3,3-dimethyl-1,2,3,4-tetrahydronaphthalene (49). A mixture of bromohydrin 48 (6.9 g, 25 mmol) and KOH pellets (15 g, 0.27 mol) in dry Et_2O (1 L) was vigorously stirred at room temperature for 48 h. Filtration and evaporation

gave the epoxide 49 (4.5 g, 91%) as a gum which was used directly without purification: NMR (CDCl₃) δ 0.85 [s, 3 H, C(Me)₂], 1.35 [s, 3 H, C(Me)₂], 2.20 (q, 15, 2, 1 H, CH₂), 2.70 (d, 15, 1 H, CH₂), 3.20 (q, 4, 2, H-2), 3.75 (d, 4, H-1), 7.05 (d, 8, H-5), 7.57 (m, H-6 and H-8).

trans-1-Amino-7-cyano-3,3-dimethyl-1,2,3,4-tetrahydro-2-naphthol (50). A solution of compound 49 (3.5 g, 18.6 mmol) in EtOH (50 mL) and NH₄OH solution (100 mL, 0.88) was stirred at room temperature for 10 days. EtOAc (50 mL) was added to the solution and the mixture extracted with dilute HCl. The acidic extracts were made basic with NaOH solution and extracted with EtOAc. The organic extract was washed with H₂O and brine and dried. Filtration and evaporation gave compound 50 as a solid (2.0 g, 53%) with mp 104–106 °C: mass spectrum (C₁₃H₁₆N₂O) found *m/z* 216.1279, calcd 216.1263.

trans-7-Cyano-3,3-dimethyl-1-(2-oxopyrrolidinyl)-1,2,3,4-tetrahydro-2-naphthol (13). A solution of amino alcohol 50 (0.5 g, 2.3 mmol), Et₃N (0.5 mL, 3.5 mmol), and 4-chlorobutyl chloride (0.33 g, 2.3 mmol) in CH₂Cl₂ (35 mL) was stirred at room temperature for 1 h. The solution was poured into dilute HCl, and the organic layer was separated and washed with Na₂CO₃ solution and dried. Filtration and evaporation gave the crude amide (0.8 g) which was dissolved in dry THF (60 mL). To this solution was added 80% NaH (75 mg, 2.5 mmol), under N₂. The mixture was stirred at room temperature for 1.5 h, and then poured cautiously into H₂O and extracted with EtOAc. The organic extract was washed with brine and dried. Filtration, evaporation, and recrystallization gave compound 13 (0.35 g; see Table I): NMR (CDCl₃) δ 0.95 [s, 3 H, C(Me)₂], 1.20 [s, 3 H, C(Me)₂], 1.95–2.30 (m, 2 H, NCH₂CH₂), 2.45 (br s, OH), 2.50–2.80 (m, 4 H, PhCH₂ and COCH₂), 2.85–3.50 (m, 2 H, NCH₂), 3.70 (d, 10, H-2), 5.25 (d, 10, H-1), 7.15–7.55 (m, 3 ArH).

trans-1-(Acetylamino)-7-cyano-3,3-dimethyl-1,2,3,4-tetrahydro-2-naphthol (14). Acetyl chloride (0.17 mL, 2.4 mmol) was added to a stirred solution of amino alcohol 50 (0.52 g, 2.4 mmol) and Et₃N (0.5 mL, 3.5 mmol) in CH₂Cl₂ (75 mL). The reaction mixture was allowed to stand for 36 h at room temperature. Water was added to the solution and the organic layer separated. The organic extract was washed with 2 N HCl, Na₂CO₃ solution, H₂O, and brine and dried. Filtration, evaporation, and recrystallization of the residue gave compound 14 (0.22 g) as colorless microcrystals (see Table I).

trans-1-(Benzoylamino)-7-cyano-3,3-dimethyl-1,2,3,4-tetrahydro-2-naphthol (17). A solution of amino alcohol 50 (0.22 g, 1.02 mmol), Et₃N (0.4 mL, 2.8 mmol), and PhCOCl (0.145 g, 1.03 mmol) in CH₂Cl₂ (30 mL) was maintained at room temperature for 18 h. The solution was poured into dilute HCl, and the layers were separated. The aqueous phase was extracted with CH₂Cl₂, and the combined organic extract was washed with Na₂CO₃ solution and dried. Filtration, evaporation, and recrystallization gave compound 17 (230 mg) as colorless needles (see Table I).

trans-7-Cyano-3,3-dimethyl-1-(*N,N'*-methylureido)-1,2,3,4-tetrahydro-2-naphthol (19). MeNCO (60 mg, 1.05 mmol) was added to a solution of amino alcohol 50 (0.22 g, 1.02 mmol) in CH₂Cl₂ (20 mL). The solution was left at room temperature for 3 h and then evaporated to give a residue which was recrystallized to give compound 19 (0.19 g; see Table I).

7-Cyano-3,3-dimethyl-1-(2-oxopyrrolidinyl)-3,4-dihydro-naphthalene (27). 2-Pyrrolidinone (0.51 g, 6 mmol) in DMSO (5 mL) was added to a suspension of 80% NaH (0.18 g, 6 mmol) in DMSO (5 mL), and the mixture was stirred for 1 h at room temperature. A solution of epoxide 49 (1.0 g, 5 mmol) in DMSO (10 mL) was added dropwise, and the solution was stirred for 18 h. The mixture was cautiously diluted with H₂O and extracted with EtOAc. The extract was washed with H₂O and brine and dried. Filtration, evaporation, and chromatography on silica gel using EtOAc–pentane as eluent gave compound 27, which was recrystallized (0.25 g) as pale yellow prisms (see Table I).

trans-4-Acetyl-6-cyano-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ol (16). A solution of 1.7 M *n*-BuLi in hexane (29.6 mL, 0.05 mol) was added to a cooled solution of diisopropylamine (5.16 mL, 0.05 mol) in DME (25 mL) at such a rate as to keep the temperature at 0 °C. The reaction mixture was stirred for an additional 15 min, before addition of *tert*-butyl acetoacetate¹² (3.86 mL, 0.023 mol) during 10 min, at 0 °C. The

reaction mixture was allowed to warm to room temperature, and epoxide 51 (1.0 g, 5 mmol) in DME (10 mL) was added to it. The reaction mixture was stirred for 20 h at room temperature and then cooled to 0 °C. HCl (32 mL of 10%) was added slowly to the orange mixture, followed by H₂O (20 mL), and the resulting solution was extracted with Et₂O. The organic phase was dried, filtered, and evaporated, and the residue was chromatographed on silica gel using a pentane–10% EtOAc in pentane gradient elution to give compound 52 (0.65 g, 37%) which was recrystallized from EtOAc–pentane: mp 121.5–122.5 °C. Anal. (C₂₀H₂₅NO₅) C, H, N.

To a solution of compound 52 (1.0 g, 2.8 mmol) in EtOH (50 mL) was added NaOH (0.28 g, 7 mmol) in H₂O (10 mL). The reaction was refluxed for 12 h and cooled, and H₂O (10 mL) was added. The solution was partially evaporated, acidified with dilute HCl, and extracted with EtOAc. The organic extract was washed with H₂O and brine and dried. Filtration and evaporation gave a gum that was radially chromatographed using a pentane–EtOAc gradient elution to give a gum that was recrystallized to give compound 16 (0.25 g; see Table I): NMR (CDCl₃) δ 1.20 [s, 3 H, C(Me)₂], 1.49 [s, 3 H, C(Me)₂], 2.32 (s, 3 H, COMe), 2.80–3.65 (m, 5 H, CH₂, H-4, H-3, and OH), 6.86 (d, 10, H-8), 7.30–7.50 (m, H-5 and H-7).

trans-6-Cyano-3,4-dihydro-*N*-methyl-2,2-dimethyl-2H-1-benzopyran-4-acetamide (21). A 1.5 M solution of *n*-BuLi in hexane (6.5 mL, 10 mmol) was added dropwise to a solution of diisopropylamine (1.4 mL, 10 mmol) in dry THF (10 mL) at 0 °C, under N₂. A solution of *N*-methyl-*N*-(4-methoxybenzyl)-acetamide (1.93 g, 10 mmol) in THF (10 mL) was then added, and the solution was stirred for 0.5 h. A solution of epoxide 51 (2.0 g, 10 mmol) in THF (20 mL) was added to the mixture, which was allowed to attain room temperature and then refluxed for 2 h. The mixture was cooled and partitioned between EtOAc and H₂O. The organic layer was washed with dilute HCl, Na₂CO₃ solution, and brine and dried. Filtration and evaporation gave a gum which was triturated with 10% EtOAc–pentane to give a solid which was recrystallized from EtOAc–petroleum ether to give compound 53 (1.7 g; Scheme III) as a colorless solid with mp 156–157 °C. Anal. (C₂₃H₂₆N₂O₄) C, H, N.

A solution of compound 53 (0.5 g, 1.3 mmol) in MeSO₃H (5 mL, 0.08 mol) was stirred at room temperature for 6 days. Water was added to the solution which was extracted with EtOAc. The organic extract was washed with NaHCO₃ solution and dried. Filtration, evaporation, and chromatography on silica gel using pentane–EtOAc in a gradient elution gave compound 21 (40 mg; see Table I).

trans-6-Cyano-3,4-dihydro-2,2-dimethyl-4-[[*N,N*-dimethylamino]carbonyl]methyl]-2H-1-benzopyran-3-ol (22). A 1.5 M solution of *n*-BuLi in hexane (6.5 mL, 10 mmol) was added to a solution of diisopropylamine (1.4 mL, 10 mmol) in THF (10 mL) at 0 °C under N₂. A solution of *N,N*-dimethylacetamide (0.95 mL, 10 mmol) in THF (10 mL) was added to the solution which was stirred for 0.5 h. A solution of epoxide 51 (2.0 g, 10 mmol) in THF (20 mL) was added to the reaction mixture which was refluxed for 2 h. The mixture was cooled and partitioned between EtOAc and H₂O, and the organic layer was washed with dilute HCl, Na₂CO₃ solution, and brine and dried. Filtration, evaporation, and trituration with EtOAc–pentane gave a solid which was recrystallized to give compound 22 (0.7 g) as colorless plates (see Table I): NMR (CDCl₃) δ 1.20 [s, 3 H, C(Me)₂], 1.50 [s, 3 H, C(Me)₂], 2.70–3.70 (m, 4 H, CH₂, H-3 and OH overlapping), 3.05 (s, 3 H, NMe), 3.10 (s, 3 H, NMe), 5.20 (m, H-4), 6.85 (d, 8, H-8), 7.40 (m, H-5 and H-7).

trans-6-Cyano-3,4-dihydro-2,2-dimethyl-4-(*N*-methyl-2-oxo-3-pyrrolidinyl)-2H-1-benzopyran-3-ol (23). A 1.5 M solution of *n*-BuLi in hexane (6.7 mL, 10 mmol) was added dropwise to a stirred solution of diisopropylamine (1.4 mL, 10 mmol) in THF (10 mL) at 0 °C, under N₂. A solution of *N*-methylpyrrolidone (0.96 mL, 10 mmol) in THF (20 mL) was added to the solution, followed after 0.5 h by a solution of epoxide 51 (2.0 g, 10 mmol) in THF (20 mL), and the reaction mixture was refluxed for 2 h. The reaction mixture was cooled and partitioned between EtOAc and H₂O. The organic layer was washed with dilute HCl, Na₂CO₃ solution, and brine and dried. Filtration, evaporation, and recrystallization gave compound 23 (0.3 g; see Table I).

Pharmacological Testing. All of the test compounds were evaluated for antihypertensive activity in conscious spontaneously hypertensive rats (14-24 weeks old), derived from the Japanese (Okamoto) strain. Animals with systolic blood pressure >180 mmHg (1 mmHg = 133 Pa) were considered to be hypertensive.

Systolic blood pressure was recorded by the tail-cuff method using a W+W B.P. recorder, Model No. 8005; each determination was the mean of at least six recordings. Blood pressure measurements were made prior to the oral administration of test compound and at intervals for up to 6 h postdose.

All compounds were administered (via an oral dosing needle placed in the esophagus) as a solution or suspension in 1% w/v methylcellulose solution.

With the use of the above procedure, vehicle alone typically had little or no effect on blood pressure apart from a slight reduction (by 5-10%) at 6 h postdose.

Acknowledgment. We wish to thank Milena Boschetti, Frances Hicks, Graham Moore and Roberto Rigolio for skilled technical assistance.

Substrate Analogue Renin Inhibitors Containing Replacements of Histidine in P₂ or Isosteres of the Amide Bond between P₃ and P₂ Sites

Peter Raddatz,* Alfred Jonczyk, Klaus-Otto Minck, Claus Jochen Schmitges, and Jan Sombroek

E. Merck Darmstadt, Preclinical Pharmaceutical Research, Frankfurter Strasse 250, D-6100 Darmstadt, Germany.

Received February 22, 1991

Incorporation of β -alanine or γ -aminobutyric acid in position P₂ of ACHPA or Leu Ψ [CHOHCH₂]Val-based tetrapeptides gave highly active renin inhibitors (compounds V, VI, and XVII) with high specificity for renin and a remarkable stability against chymotrypsin. Replacement of the amide bond between P₂ and P₃ by isosteres (ketomethylenes, hydroxyethylenes, and the corresponding thio-insertion analogues) led to compounds (VIII-XIII, XVIII, and XIX) with renin inhibitory activity in the nanomolar range. Oral activity was achieved by incorporation of polar functionalities at the N-terminus of β -alanine-containing tetrapeptides. One of these compounds (XXVIII) was chosen for further studies. This inhibitor demonstrated excellent efficacy and a long duration of action after intravenous and oral administration to cynomolgus monkeys.

Introduction

The search for orally active renin inhibitors as therapeutic agents for the treatment of hypertension and congestive heart failure continues to represent a challenging target for medicinal chemists.¹ Analogues of the angiotensinogen region flanking the bond split by renin have turned out to be very potent and specific inhibitors of renin. However, the high affinity of these angiotensinogen analogues for human renin is often associated with fast hydrolysis between P₃ and P₂ sites² by the intestinal serine protease chymotrypsin.

Since stability against proteolytic attack in the digestive tract is a requirement for orally active peptides,³ we focused our synthetic efforts on angiotensinogen analogues that are resistant to chymotrypsin and that retain a high specificity and high inhibitory potency for human renin.

Proteolytic stability has been achieved by incorporation of *N*-Me-histidine in P₂,⁴ by alteration of the phenylalanine

residue in P₃,⁵ and by isosteric replacement of the amide bond connecting the P₃ and P₂ sites.⁶ The latter approach led to inhibitors with moderate in vitro activity.

In this paper our results of replacing histidine in P₂ and of the isosteric substitution of the amide bond between P₃ and P₂ sites are described. We expected that resistance to proteolytic degradation in the digestive tract would lead to longer duration of action after intravenous and oral administration.

- (1) (a) Greenlee, W. Renin Inhibitors. *J. Med. Res. Rev.* 1990, 10, 173-236. (b) Greenlee, W. Renin Inhibitors. *J. Pharm. Res.* 1987, 4, 364-374. (c) Wood, J. M.; Stanton, J. L.; Hofbauer, K. G. Inhibitors of Renin as Potential Therapeutic Agents. *J. Enzyme Inhib.* 1987, 1, 169-185. (d) Kleinert, H. D. Renin Inhibitors: Discovery and Development. *Am. J. Hypertens.* 1989, 2, 800-808.
- (2) Schechter, J.; Berger, A. On the Size of the Active Site in Proteases. I. Papain. *Biochem. Biophys. Res. Commun.* 1967, 27, 157-162. P_n-P_n refer to the side-chain position of the peptide substrate.
- (3) Humphrey, M. J.; Ringrose, P. S. Peptides and Related Drugs: A Review of Their Absorption, Metabolism, and Excretion. *Drug. Metab. Rev.* 1986, 17, 283-310.

- (4) Thaisrivongs, S.; Pals, D. T.; Harris, D. W.; Kati, W. M.; Turner, S. R. Design and Synthesis of a Potent and Specific Renin Inhibitor with a Prolonged Duration of Action in Vivo. *J. Med. Chem.* 1986, 29, 2088-2093.
- (5) (a) Plattner, J. J.; Marcotte, P. A.; Kleinert, H. D.; Stein, H. H.; Greer, J.; Bolis, G.; Fung, A. K. L.; Bopp, B. A.; Luly, J. R.; Sham, H. L.; Kempf, D. J.; Rosenberg, S. H.; Dellaria, J. F.; De, B.; Merits, I.; Perun, T. J. Renin Inhibitors. Dipeptide Analogues of Angiotensinogen Utilizing a Structurally Modified Phenylalanine Residue to Impart Proteolytic Stability. *J. Med. Chem.* 1988, 31, 2277-2288. (b) Bühlmyer, P.; Caselli, A.; Fuhrer, W.; Götsche, R.; Rasetti, V.; Rüeger, H.; Stanton, J. L.; Criscione, L.; Wood, J. M. Synthesis and Biological Activity of Some Transition State Inhibitors of Human Renin. *J. Med. Chem.* 1988, 31, 1839-1846. (c) Iizuka, K.; Kamijo, T.; Harada, H.; Akahane, K.; Kubota, T.; Umeyama, H.; Ishida, T.; Kiso, Y. Orally Potent Human Renin Inhibitors Derived from Angiotensinogen Transition State: Design, Synthesis, and Mode of Interaction. *J. Med. Chem.* 1990, 33, 2707-2714.
- (6) Kaltenbronn, J. S.; Hudspeth, J. P.; Lunney, E. A.; Michniewicz, B. M.; Nicolaidis, E. D.; Repine, J. T.; Roark, W. H.; Stier, M. A.; Tinney, F. J.; Woo, P. K. W.; Essenburg, A. D. Renin Inhibitors Containing Isosteric Replacements of the Amide Bond Connecting the P₃ and P₂ Sites. *J. Med. Chem.* 1990, 33, 838-845.